Genmab — August 2017

[polle1]

Tak Sukkeralf, blev sgu' lige lidt forvirret

[kkjoel]

Fra SGENs
2017-Q2 rap: "As of June 30, 2017, Seattle Genetics had $473.0 million in cash, cash equivalents and investments."

[E_L]

Dara now available in Argentina
http://www.infobae.com/salud/ciencia/2017/08/09/una-revolucionaria-terapia-biologica-da-esperanza-a-personas-con-mieloma-multiple/

[Legolas23]

Thank you EL

[gentogen]

Abstracts accepted for presentation at ESMO 2017 as Proffered Paper (oral presentation), Poster Discussion and Poster will be published online on the ESMO website at 00:05 CEST on Thursday, 31 August 2017.

[Sukkeralf]

Fra Xencor transcript:

[Sukkeralf]

Sure, sure. So, the CD38 x CD3 targeting program that was part of our Amgen collaboration. I guess, we did that deal in September of 2015, it’s now two years. I know that they are still active advancing it.

[Sukkeralf]

I am hopeful that they will have it in the clinics soon. I can’t really say because, that program is fully outlicensed to them and we are just watching them as they progress it. Yes, we are very excited to see that one can get in the clinic very soon.

[Sukkeralf]

Desuden forventer de at Novartis kommer med de første data på CD123/CD3 og CD20/CD3 i 2018 - det bliver lidt spændende at følge med i

[E_L]

good find. I am very happy with the answer from Jan on the question of competition and CAR-T. I think his answer confirmed exactly your view didn't it Sukk
eralf?

[Sukkeralf]

Og her er det studie med isatuximab plus Sanofis egen PD-1

[Sukkeralf]

ClinicalTrials.gov

(clinicaltrials.gov)

[Sukkeralf]

E L - yes indeed but again CAR-T is something we need to constantly follow because of the very impressive results. Now two CAR-T targeting BCMA in the clinic

[Bulder]

Jeg fandt 8 bcma-rettede car-t studier på ct: https://clinicaltrials.gov/ct2/results?cond=&term=car-t+and+bcma&cntry1=&state1=&Search=Search Og har stadig ikke helt forstået, hvad det er Kite og Bluebird kan patentere. At udtage T-celler, omprogrammere, og genindsætte dem, står vel enhver frit for?

[Bulder]

Og hvis metoden ikke kan patenteres, er der jo ikke noget forretningsgrundlag - eller?

[Solsen]

Dejligt comeback. Over MA200 igen.

[JKY_VH]

Ja, det er godt at gå på weekend med:-)

[Thomas]

Nogen der har kommentarer til denne?
http://www.nasdaq.com/press-release/cellectar-biosciences-clr-131-achieves-overall-survival-of-greater-than-22-months-in-advanced-20170808-00803

[Solsen]

Kursudviklingen tyder ikke på at man tror meget på stoffet. OS er også lidt underlig størrelse at bruge. PFS var lettere at vurdere på for os. Tror ikke jeg har set dara har OS (overall survival) på datasets.

[Bulder]

I et slideset fra en hollandsk konference, hvor Winkel optrådte, har jeg set median OS for dara mono i Sirius og gen501 på 20,1 md. Jeg kan ikke linke, da det er noget jeg har på harddisken og kan ikke huske, hvor jeg har fundet det.